

First Quarter 2011 Financial Results (Supplemental Information)



May 5, 2011

This presentation includes forward-looking statements that are subject to many risks and uncertainties. These forward-looking statements, such as statements about Amyris's short-term and long-term growth, can sometimes be identified by use of terms such as "intend," "expect," "plan," "estimate," "future," "strive," and similar words. These statements involve many risks and uncertainties that may cause actual results to differ from what may be expressed or implied in these statements. These risks are discussed in our Securities and Exchange Commission filings and reports, including the risks identified under the section captioned "Risk Factors" in our annual report on Form 10-K filed on March 14, 2011. We disclaim any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.



Headlines



CONFIDENTIAL [3

AMYRIS

1st Commercial Plant at Biomin








São Martinho Site Preparation Underway



Technology Milestone



* Yield observed in fermentation of a particular strain at a particular scale




De-risking Production Volume

Production Outlook 2011-2012 Production (Millions of liters) 3 contract 50 manufacturing sites 40 Facility at 3rd party 30 site 20 São Martinho JV 10 construction on 0 schedule 2011 2012



Partnerships and Customers Support Growth Outlook






Expanding Beyond Farnesene to Grow Product Opportunities

FINISHED PRODUCTS IN 6 VERTICALS

AMYRIS




C5 and C10 opportunities added to existing C15 roadmap

Addressable markets

2011	2012	2013	2014	2015	2016	Chemical example	Fuel example
						Hexene	
Polyketides (C2n)						Octene	
& CarotenoidsTAM:						Decene	
\$15B (2015)					Adipic acid	
						Isoprene	
Additi pathw	onal isopren	noid					
-	ays \$13B (2015)					Pinene	Biojet
	soprene)				•	Limonene	
C10s	soprene)					Myrcene	
CIUS							
C15s							
C15s	ne					Squalane	Diesel
C15s BioFe				_,		Squalane Emollients	Diesel
C15s	tives					-	Diesel

Accelerating Growth in Selected Verticals





2011 Outlook: Key Metrics



- (1) GAAP Operating Expense outlook would also include ~\$20 million stock compensation expense
- (2) Excludes CapEx for Paraíso pending determination of which funding option we will pursue



Key Milestones to Build Value

